September 20, 2017: Positive Phase III data for Alnylam’s RNA interference treatment for hereditary ATTR amyloidosis with polyneuropathy has caused shares of company stock to spike more than 23 percent in premarket trading.
September 20, 2017: Vivek Ramaswamy is at it again. The 31-year-old former hedge-fund manager just launced Datavant, a company that will utilize artificial AI to improve clinical trials.
September 20, 2017: Earlier this year, MannKind was cited as a company that could disappear entirely by 2019. Its inhaled form of insulin, Afrezza, bombed in the marketplace, Sanofi abandoned a sales and marketing deal, and the company’s cash was dwindling at an alarming rate.
September 20, 2017: Corbus has its eyes on growth. The company is moving into a much larger headquarters in Norwood, Mass. that is expected to triple its available space and allow for new hires.